title: Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia.
abstract: The aim of this study was to evaluate the metabolic syndrome (MS) criteria and also to investigate the effects of MS on medical treatment, clinical course and personal and social performance in patients with schizophrenia. One hundred-sixteen patients with schizophrenia were included in the study. Measurements of MS were calculated in all patients. Brief Psychiatric Rating Scale, Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms, Calgary Depression Scale for Schizophrenia, Personal and Social Performance Scale (PSP) were applied. The frequency of MS according to IDF criteria was 42.2 % among the patients. There was no significant difference between patients with and without MS in terms of age. The ratios of MS were 62.5 % for the group taking typical and atypical antipsychotics together and 35.7 % for the group taking two or more atypical antipsychotics together. The duration of disorder in patients with MS was higher than those without MS. Furthermore there was no significant difference between the schizophrenic patients with and without MS, in terms of PSP scores. Our findings showed that the duration of illness, high scores of BMI, use of clozapine or concurrent use of typical and atypical antipsychotics, depressive and negative symptoms of schizophrenia were significant risk factors for the development of MS.
authors.affiliation: Department of Psychology, Işık University, 34398 , Istanbul, Turkey.
authors.forename: Omer
authors.initials: O
authors.lastname: Saatcioglu
authors.affiliation: Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Bakırköy Prof. Dr. Mazhar Osman Ruh Sağlığı ve Sinir Hastalıkları E. A. Hastanesi, Bakırköy, 34147, Istanbul, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Kalkan
authors.affiliation: Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Bakırköy Prof. Dr. Mazhar Osman Ruh Sağlığı ve Sinir Hastalıkları E. A. Hastanesi, Bakırköy, 34147, Istanbul, Turkey. nurhanfistikci@gmail.com.
authors.forename: Nurhan
authors.initials: N
authors.lastname: Fistikci
authors.affiliation: Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Bakırköy Prof. Dr. Mazhar Osman Ruh Sağlığı ve Sinir Hastalıkları E. A. Hastanesi, Bakırköy, 34147, Istanbul, Turkey.
authors.forename: Sakire
authors.initials: S
authors.lastname: Erek
authors.affiliation: Ankara Numune Training and Research Hospital Psychiatry Clinic, Altındağ, 06100, Ankara, Turkey.
authors.forename: Kasim Candas
authors.initials: KC
authors.lastname: Kilic
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D015897:Comorbidity; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000453:epidemiology* / Q000523:psychology*; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology*; D012565:Schizophrenic Psychology; D012919:Social Behavior; D014421:Turkey / Q000453:epidemiology; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents
keywords: Antipsychotics; Functionality; Metabolic syndrome; Schizophrenia